SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: Bull-like who wrote (7331)4/1/1999 4:22:00 PM
From: BigKNY3  Respond to of 9523
 
Glaxo Seeks Merger to Expand R&D, Add New Drugs, Analysts Say

London, April 1 (Bloomberg) -- Glaxo Wellcome Plc, the world's No. 3 drugmaker, is seeking to merge with a rival to bolster its research and add the kinds of billion-dollar pills that Pfizer Inc. and Warner-Lambert Co. sell, analysts said.

Three U.K. newspapers have reported that Glaxo had talked with New York-based Bristol-Myers Squibb Co. about a merger that would create the world's largest drugmaker. Both companies have declined to comment on the talks.

Glaxo last year attempted and failed to merge with fellow U.K. drugmaker SmithKline Beecham Plc. Glaxo Chairman Richard Sykes has said consolidation is inevitable in the drug industry, where no company holds more than 5 percent of the $300 billion market, and research and development costs are rising.

''Glaxo has said it is looking for a deal,'' said Barney Rosen, an analyst with Argus Research. ''It's a matter of figuring out who's left to dance with.''

In Europe, Roche Holding AG, Bayer AG and Novartis are considered likely to seek merger partners in coming years. Among U.S. companies, only a few have indicated they're looking at mergers.

American Home Products Corp. had unsuccessful merger talks early in 1998 with U.K.-based SmithKline Beecham. SmithKline later had unsuccessful merger talks with Glaxo and analysts have said SmithKline remains Glaxo's first choice for a partner.

Boosting Profit

American Home also last year failed in an attempt to merge with Monsanto Co. American Home and Monsanto are the rare major U.S. drugmakers that are having a hard time boosting per-share profit each year. For their rivals, new blockbuster drugs are boosting earnings.

With the introduction of Viagra in April 1998, Pfizer Inc.'s 1998 net income rose 27 percent to $2.63 billion. And sales of a 2-year-old schizophrenia medicine Zyprexa helped boost Eli Lilly & Co.'s 1998 profit 23 percent to $2.18 billion.

Drugmakers are most likely to merge or make large acquisitions when they are facing a crisis, such as loss of patents on top-selling drugs or setbacks in their research programs, said Linda Miller, who manages the $250 million Health Sciences Fund for John Hancock Advisers Inc.

''The wind is at the back of the U.S. drug industry,'' Miller said. ''There are very few broken companies out there.''

Glaxo isn't broken. Still, its goal of boosting per-share profit by at least 10 percent is more modest that the results the most successful U.S. drugmakers already are achieving. For example, sales of a 2-year-old cholesterol drug, Lipitor, boosted Warner-Lambert Co.'s 1998 profit 44 percent to $1.3 billion.

In 1998, Glaxo earned 1.84 billion pounds ($2.96 billion) on sales of 7.980 billion pounds ($12.8 billion), little changed from its year-earlier results.

Victory

Still, these sluggish results represent a victory of sorts for Glaxo and Sykes. Loss of patent protection and competition from new drugs caused steep declines in sales of its top sellers in recent years.

Sales of the ulcer medicine Zantac declined 42 percent to 757 million pounds ($1.22 billion) in 1998 from the year before. The drug had peak sales of 2.3 billion pounds in 1994 before competition from drugs such as Astra AB's Prilosec began eroding sales.

Sales of Glaxo's herpes medicine Zovirax fell 27 percent to 403 million pounds ($647 million).

Glaxo was helped in part by its 1995 acquisition of Wellcome, maker of the AIDS drug AZT. Adding that pill to Glaxo's own AIDS drugs helped the company dominate that growing market. It also got Zovirax and Zyban, a smoking cessation drug, from Wellcome.

Research & Development

With the worst of the patent expirations behind it, Glaxo may now seek a merger to boost research and development of new drugs. It also could use a merger to acquire more drugs that it could count on for billion-dollar annual sales -- the kind that have fueled growth for U.S. companies, analysts said.

''We're not too impressed with their pipeline in the short term,'' said Argus' Rosen.

Among the best prospects in Glaxo's research programs is a drug for irritable-bowel syndrome, Lotronex. It could have sales of $675 million by 2002, according to estimates published by SG Cowen.

If Glaxo had merged with SmithKline, it would have added Paxil, a depression drug that could achieve sales of $2 billion this year. SmithKline also could begin sales this year of a new diabetes drug, Avandia that analysts expect to reach $1 billion in annual sales within a few years of introduction. Avandia could win U.S. approval in a few months.

Prospects Improved

Avandia's prospects have improved since Glaxo and SmithKline ended their own merger talks in February 1998. Then, it seemed Avandia would have to compete with a well-established rival medicine, Rezulin. Rezulin, licensed by Warner-Lambert from Japan's Sankyo Co., had 1998 sales of $748 million. Analysts once had expected it to reach $1 billion in time.

Instead, analysts now expect Rezulin sales to drop after Avandia and another new diabetes pill, Takeda Chemical's Actos are approved. Increased safety concerns about Rezulin led a U.S Food and Drug Administration advisory panel to last week suggest the drug be used only when other diabetes treatments have failed.

''SmithKline has a potential blockbuster in hand,'' said Hemant Shah, an independent industry analyst. ''If it launches well, then the pressure to merge could be off SmithKline.''

A merger with Bristol-Myers, the world's No. 5 drugmaker, would widen Glaxo's lineup of drugs, too. Bristol-Myers has two drugs with more than $1 billion in 1998 sales, the cholesterol reducer Pravachol and the cancer medicine Taxol. Analysts estimate sales of Bristol-Myers' diabetes pill Glucophage could top $1 billion in 1999.

Not Looking for Partners

With new drugs and skillful marketing boosting sales for their companies, the chief executives of Eli Lilly & Co., Schering-Plough Corp. and Pharmacia & Upjohn Inc. all have said in the past year that they are not looking for merger partners.

Although Merck & Co. will lose patents by 2001 on drugs with about $5 billion in combined sales, the company too has said it will not seek a merger partner.

''You can pretty much put Pfizer to the side as well,'' said John Hancock's Miller said.

Part of Pfizer's current success may stem from shunning mergers, said Richard Stover, an analyst with Arnhold and S. Bleichroeder.

Pfizer didn't participate in the wave of mergers that swept through the drug industry from 1989 through 1996. In those years, Bristol-Myers added Squibb, SmithKline joined with Beecham, Pharmacia merged with Upjohn, Sandoz and Ciba-Geigy AG formed Novartis and Hoechst AG bought Marion Merrell Dow Inc.

Spared the distraction of having to combine two companies, Pfizer management focused on getting new drugs to market and building the sales force needed to sell them, analysts have said.

Meanwhile, rivals such as Pharmacia and Bristol-Myers had to do the work needed to combine two organizations. In Pharmacia's case, this including creating a new headquarters in London and then relocating it to New Jersey within the combined company's first three years of existence.

13:02:15 04/01/1999



To: Bull-like who wrote (7331)4/1/1999 4:28:00 PM
From: BigKNY3  Respond to of 9523
 
Investors Stick to Big Names in Quarter
By ROBERT D. HERSHEY Jr.

04/01/99
The New York Times
Page 8, Column 1

In its final sprint to the 10,000 mark, a peak once scarcely imagined, the Dow Jones industrial average showed that stock market investors intensified what had already seemed an inexhaustible preference for the biggest and best.

''It was all the big names -- the big caps,'' said Alfred E. Goldman, chief market strategist at A. G. Edwards in St. Louis, in reviewing the first three months of 1999 yesterday, as managers finished dressing their portfolios for client inspection. ''We're in a very selective market, so the deal is, you've got to buy the big-name stocks.''

Yesterday's action, however, was not entirely a matter of professionals adding recent winners and shedding losers, since the market suffered a late sinking spell that pushed the Dow 127.1 points lower to pare its gain for the quarter to 6.6 percent.

The Standard & Poor's 500, also dominated by large companies, lost a proportionally similar amount to finish the quarter ahead by 4.6 percent.

It was the first time since the final quarter of 1996 that the Dow beat the S.& P., and it did so despite a 35 percent skid by Philip Morris Companies. Much of that slide came this week after an Oregon jury ordered the company to pay $81 million in damages to the family of a Marlboro smoker who died of cancer.

By contrast, Standard & Poor's indexes of medium-sized and small companies slumped 7 percent and 9 percent, respectively.

''You still have the large-capitalization, global growth companies leading the market and still have the narrowness that prevailed last year,'' said Timothy E. O'Grady, senior portfolio manager for First Capital Group in Morristown, N.J.

Software, computer and many other high-technology companies also sparkled, with Microsoft rising 29 percent, to finish at $89.625, where its total value surpassed $450 billion, 25 percent more than the No. 2 General Electric.

The Nasdaq market, which is heavily weighted with technology, spurted 12 percent over the winter, with CMGI, which develops and operates Internet and direct marketing companies, soaring 244 percent to finish at $183.0625. Amazon.com, the Internet bookseller, jumped 61 percent, to $172.1875, to surpass the price of Yahoo, the leading Internet search directory, at $168.375, up 42 percent for the quarter.

Joining the high-technology winners were brokerage houses, airlines and various retailers, beneficiaries of continued avid consumer spending that itself is partly fueled by rising stock prices.

Citigroup posted the biggest gain among Dow stocks -- although it was not the biggest contributor to the average's 605-point gain -- as it climbed 29 percent, to $63.875, more than double its low of last October when foreign economic turmoil was its most intense.

Charles Schwab & Company and Donaldson, Lufkin & Jenrette paced a giant run-up in brokerage firm stocks, which were badly battered last year. Each of them rebounded 70 percent during the latest quarter. Morgan Stanley Dean Witter climbed 41 percent, Lehman Brothers and Merrill Lynch & Company by about one-third and Bear, Stearns & Company by 25 percent.

Airlines, aided by low fuel prices, as well as free-spending travelers, were led by Delta and Southwest, each up 33 percent, and UAL, which rose 30 percent. AMR, which experienced a 10-day sickout by its pilots, and U S Airways, however, edged lower.

Among retailers, Consolidated Stores, up 50 percent, and Dollar General, up 44 percent, posted some of the biggest gains. Wal-Mart Stores Inc., the No. 1 retailer, gained 13 percent to push its market capitalization -- what it would theoretically cost to buy every share -- above the $200 billion level.

Drug stocks were mixed, with American Home Products 16 percent higher, Pfizer up 11 percent and Merck up 9 percent. Abbott, Bristol-Myers and Eli Lilly all lost between 4 and 5 percent, while Warner-Lambert, maker of the controversial diabetes drug Rezulin, lost 12 percent.

Utilities weakened as interest rates crept higher, with the S. & P. utility index falling 10 percent. Nonetheless, there was little sign of faster inflation, and precious metals turned in another poor performance, with the Philadelphia gold and silver index slipping 8 percent.

Looking ahead, the Dow after millenary milestones has advanced in the following quarter on two of every three occasions, and has also done better than other market indexes. Its biggest rise was 12.5 percent after the average hit 6,000 in late 1996, according to LIM Research.com. The biggest loss was 1.2 percent in the quarter following the Dow's July 1997 surge to 8,000.

The research company also noted that the Russell 2000 underperformed the general market in the quarter following seven of the last eight 1,000-point milestones.